Crescent Biopharma (CBIO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.62
- Estimate
- -$0.64
- Surprise
- +2.8%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Crescent Biopharma (CBIO) reported a narrower loss than forecast — adjusted EPS of -$0.62 against the -$0.64 estimate (a 2.8% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CBIO Sell at 5.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +2.8% surprise compares with a -11.1% four-quarter average.
What argues against it
- Concentration risk — Pipeline: CR-001, CR-002 and CR-003
- Risk below floor (2.4 < 2.5)
- Value-trap signals (2/5): Margin compression (op margin 0.2%), Material insider selling (9 sells, 0.29% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.46
- Price target
- $27.41
- Stop
- $13.45
- Upside to target
- +89.6%
- Reward-to-risk
- 6.0:1
Model outputs from TrendMatrix’s engine as of 2026-10-13 — shown for context, not personalized investment advice.
CBIO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $537.1M
- P/E (fwd)
- -5.5
- 52-week range
- $8.72–$27.41
- Off 52-week high
- 47.2%
- RSI (14)
- 35
- Volume vs avg
- 0.27×
- Score today
- 5.2/10